Stada And Xbrane Win EU Endorsement For Ranibizumab

Ximluci, Third Biosimilar Rival To Lucentis, Receives Positive Opinion From CHMP

EU flag reflected in eye
Stada and Xbrane are eyeing the third European biosimilar ranibizumab approval • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products